CD274 and neoplasm: PD-L1 expression by tumour cells inhibits T cell-mediated killing, and there is an evolving clinical programme to block PD-L1 as a therapeutic in cancer therapy (Chen et al., 2016; Hahn et al., 2017; Huang et al., 2015).